Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 4, 2008, Pages 488-496

  Kalliokoski, A ^a   Backman, J T ^a   Kurkinen, K J ^a   Neuvonen, P J ^a   Niemi, M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GEMFIBROZIL; GLUCOSE; ORGANIC ANION TRANSPORTER 2; PLACEBO; REPAGLINIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTILIPEMIC AGENTS; AREA UNDER CURVE; BLOOD GLUCOSE; CARBAMATES; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; GEMFIBROZIL; GENOTYPE; HALF-LIFE; HEPTANOIC ACIDS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; ORGANIC ANION TRANSPORTERS; PIPERIDINES; POLYMORPHISM, GENETIC; PYRROLES;

EID: 56149107690     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.74     Document Type: Article

References (35)

1. Dornhorst, A. Insulinotropic meglitinide analogues. Lancet 358, 1709-1716 (2001).
2. Hatorp, V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacokinet. 41, 471-483 (2002).
3. Bidstrup, T.B., Bjørnsdottir, I., Sidelmann, U.G., Thomsen, M.S. & Hansen, K.T. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br. J. Clin. Pharmacol. 56, 305-314 (2003).
4. Niemi, M., Backman, J.T., Neuvonen, M. & Neuvonen, P.J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46, 347-351 (2003).
5. Niemi, M., Kajosaari, L.I., Neuvonen, M., Backman, J.T. & Neuvonen, P.J. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br. J. Clin. Pharmacol. 57, 441-447 (2004).
6. Kajosaari, L.I., Laitila, J., Neuvonen, P.J. & Backman, J.T. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin. Pharmacol. Toxicol. 97, 249-256 (2005).
7. Kajosaari, L.I., Niemi, M., Backman, J.T. & Neuvonen, P.J. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin. Pharmacol. Ther. 79, 231-242 (2006).
8. Niemi, M. et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77, 468-478 (2005).
9. Tirona, R.G., Leake, B.F., Merino, G. & Kim, R.B. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675 (2001).
10. Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. & Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513-522 (2005).
11. Moon, Y.S. & Kashyap, M.L. Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacotherapy 24, 1692-1713 (2004).
12. Wang, J.S., Neuvonen, M., Wen, X., Backman, J.T. & Neuvonen, P.J. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos. 30, 1352-1356 (2002).
13. Backman, J.T., Kyrklund, C., Neuvonen, M. & Neuvonen, P.J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685-691 (2002).
14. Ogilvie, B.W. et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos. 34, 191-197 (2006).
15. Shitara, Y., Hirano, M., Sato, H. & Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228-236 (2004).
16. Pasanen, M.K., Fredrikson, H., Neuvonen, P.J. & Niemi, M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82, 726-733 (2007).
17. Chen, C. et al. Differential interaction of 3-hydroxy-3- methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos. 33, 537-546 (2005).
18. Brøsen, K., Hansen, J.G., Nielsen, K.K., Sindrup, S.H. & Gram, L.F. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur. J. Clin. Pharmacol. 44, 349-355 (1993).
19. Lessard, E., Yessine, M.A., Hamelin, B.A., O'Hara, G., LeBlanc, J. & Turgeon, J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9, 435-443 (1999).
20. Yasui-Furukori, N. et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br. J. Clin. Pharmacol. 57, 487-494 (2004).
21. Yasui-Furukori, N., Saito, M., Uno, T., Takahata, T., Sugawara, K. & Tateishi, T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J. Clin. Pharmacol. 44, 1223-1229 (2004).
22. Kajosaari, L.I., Niemi, M., Neuvonen, M., Laitila, J., Neuvonen, P.J. & Backman, J.T. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 78, 388-399 (2005).
23. Niemi, M., Leathart, J.B., Neuvonen, M., Backman, J.T., Daly, A.K. & Neuvonen, P.J. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 74, 380-387 (2003).
24. Kirchheiner, J. et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin. Pharmacol. Ther. 80, 657-667 (2006).
25. Tornio, A., Niemi, M., Neuvonen, P.J. & Backman, J.T. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab. Dispos. 36, 73-80 (2008).
26. Tornio, A. et al. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin. Pharmacol. Ther. (2008).
27. Tornio, A., Pasanen, M.K., Laitila, J., Neuvonen, P.J. & Backman, J.T. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin. Pharmacol. Toxicol. 97, 104-108 (2005).
28. Sakaeda, T. et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm. Res. 23, 506-512 (2006).
29. Stern, R.H., Smithers, J.A. & Olson, S.C. Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine. J. Clin. Pharmacol. 38, 753-757 (1998).
30. Mc Donnell, C.G., Harte, S., O'Driscoll, J., O'Loughlin, C., Van Pelt, F.N. & Shorten, G.D. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia 58, 899-904 (2003).
31. Lau, W.C. et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107, 32-37 (2003).
32. Kalliokoski, A., Neuvonen, M., Neuvonen, P.J. & Niemi, M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J. Clin. Pharmacol. 48, 311-321 (2008).
33. Rodríguez-Antona, C. et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. (2007); e-pub ahead of print 9 October 2007.
34. Lennernäs, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42, 1141-1160 (2003).
35. Pasanen, M.K., Backman, J.T., Neuvonen, P.J. & Niemi, M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62, 409-415 (2006).